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1. Introduction
Chronic  kidney  disease  (CKD)-mineral  and  bone  disorder  (CKD-MBD)  becomes  an
important issue in CKD management [1].  CKD patients show a bone and mineral disor‐
der as follows: (i) laboratory abnormal metabolisms of calcium, phosphate, and vitamin D;
(ii) evidence of calcified tissue disturbance; (iii) and arterial calcification. Arterial calcifica‐
tion is known to be related to numerous worse symptomatic outcomes, such as ischemic
cardiovascular attacks and death [2]. The pathogenesis of vascular calcification in CKD is
complex, and instead of occurring by a simple process of calcium and phosphate precipita‐
tion, it is produced by an active process in which vascular smooth muscle cells (VSMCs)
undergo apoptosis and vesicle formation and are transformed into osteoblast-like cells that
induce matrix formation and attract  local  factors that are involved in the mineralization
process [3] (Fig. 1).
The pathogenesis of the multifactorial interactions between aging and progression of vascular
calcification remains uncertain. However, there is no doubt that end-stage renal disease (ESRD)
patients are at high risk of and have a common finding of vascular calcification due to multiple
confounders that promote the differentiation of VSMCs to osteoblast-like cells, which are able
to enhance the tissue calcium deposition process [4]. Vascular calcification has recently
reported to be associated with many traditional risk factors, aging, high blood pressure,
diabetes, and hyperlipidemia, and with nontraditional risk factors, including elevated serum
phosphate level, hyperparathyroidism, and high-dose prescription of calcium [5]. Vascular
calcification causes a decrease in vascular elasticity, an increase in pulse wave velocity [6], an
induction of cardiomyopathy [7], a decrease in coronary artery flow, and an ischemic change
(Fig. 2).
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Figure 2. Schematic representation of the clinical effects of arterial intimal and medial calcification.
Recent therapeutic regimens that are performed to suppress vascular calcification are concen‐
trated on the control of metabolic markers of skeletal disorder, including phosphate, and
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Figure 1. Relationship between calcium and phosphorus and vascular calcification.
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vitamin D. The antiosteoporosis drugs such as bisphosphonates [8] have shown therapeutic
possibility, but more additional clinical trials are needed. The ADVANCE study has recently
shown that cinacalcet and low-dose vitamin D reduce vascular and cardiac valve calcification
in hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT) [9]. This review
article describes recent progress in terms of the pathogenic mechanisms and methods of
assessing and managing vascular calcification in ESRD patients.
2. Pathophysiology and bone-associated proteins
The pathophysiology of vascular disorder in HD patients is recently recognized as different
from the pathophysiology of atherosclerotic alterations in healthy subjects [10]. Vascular
calcification progresses in association with aging, and deposition of calcium in the media is >
30-times more in the thoracic aorta at 90 years old than those at 20 years old [11]. Age-associated
medial calcinosis in arteries is also related to hypertension, diabetes, and hyperlipidemia [12],
and it is specific for arteries and does not affect other soft tissues in normal subjects. Vascular
calcification was previously considered as a passive finding, but it has recently been recognized
as an active process [13–15].
Two patterns of vascular calcification have been reported. One appears in the intimal layer
and the other occurs in the medial layer of the vessel wall which is known as in Monckeberg’s
calcification [16], and both types are related to increased mortality of HD patients [17]. Intimal
calcification is found to be related to chronic inflammatory changes and the occurrence of
plaques and occlusive lesions. This intimal type of calcification is a predictor of the advanced
atherosclerosis and is found to be seen in the aorta and coronary arteries. Medial calcification
is identified with diffuse calcium deposition and can occur independent of atherosclerosis, and
it is frequently shown in conduit arteries, including the femoral and tibial arteries [13, 16].
There are well-known changes in the arterial wall, such as intimal thickening, calcification of
elastic lamellae, an increased extracellular matrix, and deposition of collagen and a relatively
small elastic fiber content, and these findings are associated with arterial remodeling in CKD
patients [17]. Numerous bone-related proteins, including osteopontin, osteocalcin, and
osteoprotegerin (OPG), and bone morphogenetic proteins (BMPs) are associated with the
vascular remodeling, and they are found to be appeared in the calcified lesions and are known
to be related to vascular calcification [18]. VSMCs are the main component of the arterial media,
and they can transform to osteoblast-like cells in association with up-regulation of transcrip‐
tion factors, such as Runt-related transcription factor 2 (Runx2) and Msh homeobox 2 (Msx2),
which are important factors for normal bone formation [19]. This phenotypic differentiation
may be related to the deposition of calcium in the layer of VSMCs that is similar to bone
development, indicating that this type of vascular calcification is ectopic ossification. In
addition, uremic condition has been found to induce transformation of VSMCs into osteoblast-
like cells and suppresses the transformation of macrophages into osteoclasts [20]. The arteries
of HD patients demonstrate up-regulation of alkaline phosphatase activity and enhanced
expression of Runx2, which is predictor of osteogenic differentiation of VSMCs [21].
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3. Dysregulation of calcium and phosphate metabolism
Traditional risk factors, such as aging, hypertension, diabetes, and hyperlipidemia, and
various nontraditional factors, including low serum calcium levels, high serum phosphate
levels, high-dose prescription of CaCO3, chronic inflammation, and malnutrition, have been
observed in ESRD patients [22]. Patients with advanced CKD demonstrate hyperphosphate‐
mia followed by reduced renal phosphate excretion. Vascular calcification is obviously related
to impaired serum calcium and phosphate concentrations [16, 21, 23]. Elevated serum phos‐
phate concentration is found to be recognized as an arterial injury factor [24], and when
phosphate control had been poorest, vascular calcification had rapidly progressed in CKD
patients [25].
There are two different mechanisms of vascular calcification that are proposed to verify the
relationship between abnormal calcium and phosphate metabolism and vascular calcification.
Previous studies have shown that calcium is a key element in the initiation of vascular
calcification by promoting calcium deposition in VSMCs under normal phosphate metabolism
[26], and when the phosphate levels are increased, this calcium deposition has been enhanced
additionally [27]. Hyperphosphatemia may directly cause vascular injury, and it indirectly
promotes osteoblastic differentiation via a type III sodium-dependent phosphate cotransporter
(PiT-1). A previous report [28] demonstrated that an increased intracellular phosphate
concentration may directly enhance VSMCs to differentiate to calcifying cells by activating
genes. In addition, El-Abbadi et al. [29] has shown an experimental model of CKD-related
vascular calcification in which severe arterial calcification progresses only after the mice are
treated with a high-phosphate diet, indicating that hyperphosphatemia is a powerful stimu‐
lator of arterial calcification. These results suggest that high-dose phosphate and calcium
prescription is the most important risk factor in vascular calcification.
It is recognized that secondary hyperparathyroidism (SHPT) is common in ESRD patients and
appears even in the early stage of CKD. Mineral metabolism disorders, such as hyperphos‐
phatemia, is associated with the progression of CKD stage, leading to the occurrence of SHPT,
which is detected by elevated serum parathyroid hormone (PTH) concentrations and para‐
thyroid gland hyperplasia [30]. Increased PTH concentration is critical for the proliferation
and activation of osteoclasts and important for the enhanced bone resorption in these patients.
A remarkable reduction in serum 1,25-dihydroxyvitamin D [1,25(OH)2D] concentration is
detected in the early stage of CKD [31], and the decrease in 1,25(OH)2D level is associated with
renal and nonrenal mediators, such as decreased sun light exposure, reduced synthesis of the
25(OH) D precursor, and decreased dietary injection [32]. Reduced vitamin D production
occurs in parallel with CKD progression and stimulates parathyroid gland enlargement,
followed by SHPT [30].
Decreased 25(OH)D concentrations influenced survival independently of vascular calcinosis
and increased arterial stiffness, indicating that 25(OH)D may affect mortality of CKD patients
through additional mechanisms that require to be expected [33]. Active vitamin D promotes
intestinal uptake of calcium and phosphate and stimulates osteoblastic transformation of
VSMCs. Furthermore, 1,25(OH)2D has been known to play a role as a negative modulator of
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the renin–angiotensin axis, which acts an important key element in the cardiovascular system
by controlling extracellular volume and electrolyte metabolism [34]. Even though high-dose
of 1,25(OH)2D promotes arterial calcinosis [35], normal doses have been reported to inhibit
arterial calcinosis in experimental models of CKD [36].
4. Fibroblast growth factor 23 and vascular calcification
Fibroblast growth factor 23 (FGF-23) is a new regulator produced by osteoblasts, which is
associated with the regulation of phosphate and vitamin D metabolism [37]. FGF-23 has been
shown to reduce the synthesis and promote the degradation of 1,25(OH)2D. Actually,
recombinant FGF-23 suppresses renal 25-hydroxyvitamin D-1α-hydroxylase mRNA within 1
h in mice [38]. The enhanced degradation of 1,25(OH)2D by 24-hydroxylase may be related to
this phenomenon. In addition, a phosphaturic effect of FGF-23 contributes to decreased
phosphate uptake in the kidney. FGF-23 has been shown to down-regulate types IIa and IIc
sodium-phosphate cotransporters on the apical area of proximal epithelial cells [38, 39].
Klotho has been reported as a 130-kDa β-glucuronidase that catalyzes the hydrolysis of steroid
β-glucuronides [40]. The Klotho gene is mainly expressed in the kidneys, and its mutation
induces many aging-associated diseases [41]. Since the phenotype of FGF-23-knockout (KO)
mice is similar to those of Klotho-KO mice [42, 43], a common signaling pathway has been
proposed, FGF-23 receptors (FGF-Rs). FGF-23 acts via FGF receptors (FGF-Rs) in a Klotho-
dependent manner since a Klotho/FGF-R complex binds to FGF-23 with higher affinity than
FGF-R or Klotho only [44]. FGF-23 has lower affinity for its receptors, and the combination
with circulating Klotho is important to enhance the binding of FGF-23 to FGF-Rs [45]. Taken
together, the activation of FGFRs needs not only circulating FGF-23 as a ligand but also Klotho
as a specific activator those affinity attributes the selectivity on target organs.
Klotho is mainly present in the kidneys, whereas FGF-23 secretes from bone cells, and this
bone–kidney interaction is essential for physiological and pathological mechanism. According
to recent information, it is likely that this axis exerts a fundamental regulation of calcium
metabolism with Klotho and to show a more specific effect on phosphate homeostasis via the
presence of FGF-23. Both Klotho and FGF-23 affect synthesis of active vitamin D and PTH,
indicating that FGF-23 may control PTH secretion in the parathyroid glands. In support of this
mechanism, results obtained in vitro suggest that FGF-23 suppresses PTH mRNA transcription
and protein secretion in a dose-dependent manner [46]. On the other hand, PTH promotes
FGF-23 production by osteoblasts because increased FGF-23 concentrations in animals with
primary HPT occur, which is decreased by parathyroidectomy [47].
5. Inhibitors of vascular calcification
Fetuin-A is originally synthesized in the liver, and circulating fetuin-A concentrations fall
during the inflammatory process [48]. Fetuin-A is an extracellular calcium-regulatory factor
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that functions as a new inhibitor of calcium-phosphate deposition [49], suppresses calcinosis
by binding hydroxyapatite [50], and protects VSMCs from the harmful effects of calcium
overload and subsequent calcification [51]. Fetuin-A suppresses VSMC apoptosis through
death-signaling pathways: (i) it is internalized by VSMCs, concentrated in intracellular
vesicles, and secreted via vesicle release from apoptotic and living VSMCs; (ii) fetuin-A in
vesicles suppresses their ability to nucleate calcium phosphate; and (iii) fetuin-A increases
phagocytosis of vesicles by VSMCs. These results confirm finding that the internalization of
fetuin-A into VSMCs is a key finding in the inhibition of vesicle-mediated VSMC calcification
[51]. In in vitro experiments, fetuin-A has been reported to antagonize the action of TGF-β1
(transforming growth factor-β1) and inhibit osteogenesis and calcium-containing matrix
deposition in dexamethasone-treated rat bone marrow cells [49]. Moreover, fetuin-A-KO mice
show severe ectopic calcinosis in the myocardium, kidney, lung, tongue, and skin [49]. A recent
study [49] demonstrated that ESRD patients who had lower serum fetuin-A concentrations
showed a lower survival rate from cardiovascular diseases, indicating that fetuin-A is related
to the mechanism of the accelerated extraskeletal calcinosis.
Matrix Gla protein (MGP) is a matrix protein that was firstly discovered from bone [52],
and it is an important modulator of vascular calcification. To exert its biological activity,
MGP requires to be activated through interaction with vitamin K [53]. The calcification of
cartilage and blood vessels has been found to be inhibited by MGP [54]. MGP affects on
vascular  calcification  directly  by  reducing  calcium  crystal  formation  and  indirectly  by
modulating transcription factors that suppress VSMC transformation to the osteoblast-like
cells [55]. Moreover, MGP is an important factor capable of transformation of VSMCs [58].
A  decrease  in  glomerular  filtration  rate  has  been  shown  to  result  in  a  reduction  in
uncarboxylated MGP level which is related to vascular calcification [56].
The receptor activator of nuclear factor κ-light-chain-enhancer of activated B-cells (RANK),
and  RANK  ligand  (RANKL),  and  osteoprotegerin  (OPG)  might  be  associated  with  the
mechanism of vascular calcification. RANKL functions are inhibited by OPG that acts as a
decoy receptor to inhibit RANKL/RANK relationships [57]. This system may be related to
the imbalance of bone–vascular calcification interactions and could be a predictor of the
grade  of  vascular  calcification.  A  recent  study  [58]  demonstrated  that  coronary  arterial
calcification (CAC) is  significantly associated with plasma OPG values in CKD patients.
The serum OPG levels >757.7 pg/ml in CKD patients were indicator of CAC. These results
are compatible with those reported in our previous study [59]. The relationship between
serum OPG concentrations and CAC is unclear. The functional role of circulating OPG has
been found to be modulated by several factors, including the relevant association of different
tissue sources  and the contribution of  various comorbidities.  OPG has been reported to
have  protective  effect  against  vascular  calcium  deposition  in  experimental  models  [60].
Interestingly, higher OPG concentrations have been shown in patients with vascular injury,
indicating that  an elevated OPG concentration may be attribute to a  compensatory self-
defense mechanism that stimulates vascular calcification [61].
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6. Evaluation of vascular calcification
Several types of noninvasive methods are useful for screening of the detection of vascular
calcification: plain X-rays for visible calcification of the aorta and peripheral arteries; two-
dimensional ultrasound for detecting calcification of the carotid arteries and femoral arteries;
and echocardiography for the evaluation of valvular calcification; and computer tomography
(CT) is considered to be the gold standard for quantification of coronary artery and aorta
calcification.
Electron-beam CT (EBCT) and multislice CT (MSCT) are relatively sensitive methods for
quantitative assessment of vascular calcification, such as CAC, which utilize an electrocardio‐
graphic trigger capable of the evaluation of the heart in diastolic phase, thereby prohibiting
moving artifacts [62]. These methods can be usually used to assess the presence of vascular
calcifications, the evaluation of longitudinal vascular calcification, and the effect of various
treatments on vascular calcification [63]. EBCT is not available in every hospital, although most
hospitals have MSCT equipment and, with software applications to enable gated imaging, the
new MSCT can evaluate vascular calcification. However, there have been conflicting reports
concerning the relationship between the grade of CAC estimated by EBCT and the prevalence
of cardiovascular events in ESRD patients [64, 65]. The conflicting results could be confirmed
by the evidence that the arterial calcification score evaluated by MSCT is a combination of both
medial and intimal calcification, and the finding that is a limitation of the CT-based assessment.
MSCT can be used to evaluate aortic calcification [66, 67]. Conventional CT could be used to
estimate noncoronary vascular calcification, such as aortic calcification. The area of the aortic
circumference that is calcified can be estimated as an aortic calcification index (ACI). It is likely
that conventional CT is relatively inexpensive and applicable for screening of vascular
calcification. A previous study [72] utilized the conventional CT to estimate aortic calcification
in diabetic HD patients. The ACI could not be applicable to evaluate the medial/intimal
calcification.
Plain lateral-abdominal X-ray is an inexpensive method for detecting the presence of vascular
calcification in CKD patients, but it is semiquantitative, and longitudinal alterations of vascular
calcification may not be confirmed. Lateral abdominal X-ray could be utilized as an alternative
to CT [69]. The presence of vascular calcification observed on plain X-rays may give some
information concerning the pattern of the arterial wall calcification. Kauppila et al. [70] showed
the application of lateral lumbar X-rays to confirm the pattern of aortic calcification, in the area
responsible to the part of the first to the fourth lumbar vertebrae. This semiquantitative method
is a more applicable and less expensive technique for showing arterial calcification and could
be utilized for cardiovascular risk management.
We have shown a simple method to study the grade of aortic arch calcification (AoAC) using
plain chest X-ray in HD patients [71]. AoAC score (AoACS) was evaluated as a percentage of
the proportion of calcified aortic arch, and the mean AoACS was 5.0% ± 4.5% ranging from 0%
to 15%. Older age and longer dialysis duration were significant factors in the patients with
AoAC. The grade of AoAC was significantly associated with the AoAC volume measured by
MSCT. We suggest that screening HD patients for AoAC is a cost-effective method to find
Vascular Calcification in ESRD
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patients at the highest risk of cardiovascular diseases and of identifying therapy by inhibiting
vascular calcification.
7. Applicable therapy of vascular calcification
Hyperphosphatemia  is  associated with  SHPT and contributes  to  cardiovascular  and all-
cause mortality. The phosphate binders are recently utilized to treat hyperphosphatemia,
including sevelamer, lanthanum, and the calcium-based phosphate binders (CBPBs) such
as  CaCO3.  Sevelamer  is  a  calcium-free  phosphate  binder  that  does  not  increase  serum
calcium  concentrations,  enables  better  serum  phosphate  management  than  CBPBs,  re‐
duces the extent of aortic calcification in ESRD patients, and improves serum lipid profile
because it decreases low-density lipoprotein cholesterol (LDL-C) and induces the increase
in high-density lipoprotein cholesterol (HDL-C) [72]. In a clinical study consisting of 200
HD patients, Chertow et al. [73] showed that sevelamer had significantly reduced the extent
of coronary and aortic calcification compared with CBPBs after 1 year of therapy. These
results  were  reevaluated  by  other  investigators  [74],  who  demonstrated  that  sevelamer
significantly reduced the progression of vascular calcification when compared with CaCO3.
One of the possible mechanism is a strong phosphate-binding ability of sevelamer in the
intestine, without calcium overload. In the Renagel in New Dialysis study including HD
patients  with  pretreatment  CAC  scores  of  30  or  higher,  no  significant  difference  was
detected in the rate of CAC progression up to 18 months of follow-up between the sevelamer
group and CBPB group [75]. In vitro experimental studies have demonstrated that acetylat‐
ed LDL-C induces calcium deposition, whereas HDL-C reduces it in cultured VSMCs [76].
In in vivo  human studies, sevelamer has been shown to decrease LDL-C and to increase
HDL-C concentrations. This improved lipid profile may be associated with the lowering
grade  of  vascular  calcification  found after  sevelamer  therapy.  These  findings  were  con‐
firmed with the evidence that intensive LDL-C-lowering therapy with atorvastatin in the
Calcium Acetate Renagel Evaluation-2 study demonstrated similar effects on the extent of
CAC in HD patients treated with sevelamer and those treated with calcium acetate [77].
The calcium-sensing receptor (CaR) is a G protein-coupled receptor that binds calcium ions
and makes it  possible to respond to changes in the extracellular calcium ion levels [78].
CaR expression  in  the  arterial  wall  has  been  found to  be  profoundly  decreased in  HD
patients  compared  with  normal  subjects  [79].  These  results  are  compatible  with  those
reported by Alam et al.  [80],  who showed lower expression CaR in the calcified human
arteries  compared  with  those  without  calcification.  These  findings  indicate  that  CaR
expression was closely associated with vascular calcification in the vessel wall. Ivanovski
et al.  [81] showed finding of direct suppression of phosphate-stimulated calcium deposi‐
tion in cultured human VSMC in vitro by a calcimimetic R-568, through local CaR activa‐
tion.  Lopez  et  al.  [82]  examined the  effect  of  the  R-568  alone  and in  combination  with
calcitriol on the induction of vascular calcification in a uremic rat model with SHPT. The
results  of  the  experiment  indicated that  the  R-568  decreased serum PTH concentrations
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without  induction  of  vascular  calcification,  suppressed  calcitriol-stimulated  calcium
deposition  on  vasculature,  and  reduced  mortality  rate  related  to  supplementation  of
calcitriol.  They concluded that  R-568 suppresses increased serum PTH concentrations in
uremic rats and inhibits calcitriol-stimulated calcium deposition in arterial tissues.
Bisphosphonates might play a possible role in the treatment of vascular calcification because
these  agents  have been found to  eliminate  vascular  calcification in  experimental  animal
models.  Tamura  et  al.  [83]  previously  reported  that  etidronate  suppressed  calcitriol-
stimulated aortic calcium deposition in uremic rats. They showed that 2 mg/kg of etidro‐
nate was not effective but that 5–10 mg/kg of etidronate inhibited calcium deposition in
the  aorta.  In  another  experimental  study  using  cultured  bovine  VSMCs,  pamidronate
reduced arterial calcium deposition [84]. In clinical studies, etidronate has been found to
suppress and even reverse the CAC progression in some of HD patients [8,  85],  but the
mechanism is unclear. Bisphosphonates suppress bone resorption, with decreased efflux of
calcium and phosphate, limiting their deposition in the vascular tissues, or may affect the
function of the sodium/phosphate cotransporter in VSMCs [86].
There are a few prospective randomized trials available in the literature with therapeutic
interventions aimed at controlling vascular calcification and improving survival in patients
with advanced CKD. Since there is an association between CKD-MBD, vascular calcifica‐
tion and mortality, mineral balance abnormalities became an obvious target for therapeu‐
tic  interventions.  Unfortunately,  no  additional  data  have  been  published  to  change  the
perspective  in  the  KDIGO guidelines  [69].  The  EVOLVE trial  in  3883  HD patients  was
conducted to test the hypothesis that treatment with cinacalcet would reduce the risks of
death and nonfatal cardiovascular events [87]. However, no benefit was demonstrated from
using the calcimimetic agent.
8. Conclusion
Vascular calcification is highly prevalent in ESRD and independently predictive of future
cardiovascular events and mortality. Calcification occurs in both the intimal and medial layers
of vasculature, but medial calcification is the major form in ESRD patients. Medial calcification
increases arterial stiffness and pulse pressure, induces left ventricular hypertrophy, reduces
perfusion of the coronary arteries, and ultimately promotes increased cardiovascular mortal‐
ity. Vascular calcification results not from a passive deposition of calcium and phosphate but
rather is an active cell-mediated process involving vascular smooth muscle cell apoptosis and
vesicle release; muscle cell differentiation forms a contractile to osteoblast-like phenotype.
Cutting-edge scientific research on the mechanisms underlying vascular calcification is
increasingly being undertaken, and further insight into the mechanisms may lead to the
development of several types of therapeutic agents that will improve the cardiovascular
outcome in ESRD patients.
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